ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ADMA ADMA Biologics

Closed 05-03 16:00:00 EDT

6.81

+0.07

+1.04%

盘后6.81

+0.000.00%

19:10 EDT

High6.81	Low6.65	Vol2.99M
Open6.78	D1 Closing6.74	Amplitude2.37%
Mkt Cap1.58B	Tradable Cap1.55B	Total Shares231.77M
T/O20.17M	T/O Rate1.31%	Tradable Shares227.16M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ADMA","market":"US","secType":"STK","nameCN":"ADMA Biologics","latestPrice":6.81,"timestamp":1714766400000,"preClose":6.74,"halted":0,"volume":2985668,"hourTrading":{"tag":"盘后","latestPrice":6.81,"preClose":6.81,"latestTime":"19:10 EDT","volume":94355,"amount":642543.6004,"timestamp":1714777855532},"delay":0,"floatShares":227163302,"shares":231771523,"eps":-0.13,"marketStatus":"Closed","change":0.07,"latestTime":"05-03 16:00:00 EDT","open":6.78,"high":6.81,"low":6.65,"amount":20173545.121225998,"amplitude":0.023739,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.13,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1714982400000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":6.74,"preHourTrading":{"tag":"盘前","latestPrice":6.79,"preClose":6.74,"latestTime":"09:29 EDT","volume":3123,"amount":21176.3365902,"timestamp":1714742999999},"postHourTrading":{"tag":"盘后","latestPrice":6.81,"preClose":6.81,"latestTime":"19:10 EDT","volume":94355,"amount":642543.6004,"timestamp":1714777855532},"volumeRatio":1.519244},"requestUrl":"/m/hq/s/ADMA","defaultTab":"news","newsList":[{"id":"2432962231","title":"Adma Biologics (ADMA) Rises Higher Than Market: Key Facts","url":"https://stock-news.laohu8.com/highlight/detail?id=2432962231","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2432962231?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:45","pubTimestamp":1714686316,"startTime":"0","endTime":"0","summary":"Adma Biologics  closed the most recent trading day at $6.74, moving +1.05% from the previous trading session. The stock outperformed the S&P 500, which registered a daily gain of 0.91%. Elsewhere, the Dow gained 0.85%, while the tech-heavy Nasdaq added 1.51%.Coming into today, shares of the infectious disease drug developer had gained 5.04% in the past month. In that same time, the Medical sector lost 2.73%, while the S&P 500 lost 4.2%.The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release. The company is expected to report EPS of $0.05, up 266.67% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $76.7 million, reflecting a 34.77% rise from the equivalent quarter last year.Any recent changes to analyst estimates for Adma Biologics should also be noted by investors. Such recent modifications usually signify the changing landscape of near-term business trends","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T44Iwg7RbRrkaTIYz_liyQ--~B/aD00Njk7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/737ffb82e07dc8bffb77e72d153c91f2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-rises-higher-214516144.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432756716","title":"ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432756716","media":"GlobeNewswire","top":-1,"share":"https://ttm.financial/m/news/2432756716?lang=en_us&edition=fundamental","pubTime":"2024-05-02 11:00","pubTimestamp":1714618800,"startTime":"0","endTime":"0","summary":"Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., May  02, 2024  (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/02/2874013/33130/en/ADMA-Biologics-to-Report-First-Quarter-2024-Financial-Results-on-May-9-2024.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431191818","title":"What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?","url":"https://stock-news.laohu8.com/highlight/detail?id=2431191818","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2431191818?lang=en_us&edition=fundamental","pubTime":"2024-04-29 23:26","pubTimestamp":1714404360,"startTime":"0","endTime":"0","summary":"We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of its three marketed commercial products and other pipeline updates when it reports first-quarter 2024 results.Let’s see how things have shaped up for the quarter to be reported.ADMA Biologics markets plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases. The company’s top line currently comprises sales of three FDA-approved products, namely – Bivigam , Asceniv  and Nabi-HB .Revenues in the last reported quarter jumped around 48% year over year owing to strong sales of its immunoglobulin products, a trend mostly likely to have continued in the to-be-reported quarter.ADMA Biologics has an encouraging record of earnings surprise history so far. The company’s earnings beat estimates in three of the trailing four quarters and met the same on the remaining occasion. ADMA delivered a four-quarter average earnings surprise of 85.00%. In ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/whats-store-adma-biologics-adma-152600088.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431622668","title":"Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2431622668","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2431622668?lang=en_us&edition=fundamental","pubTime":"2024-04-29 20:16","pubTimestamp":1714392960,"startTime":"0","endTime":"0","summary":"Last week, two of the three major U.S. indexes — the S&P 500 and the tech-heavy Nasdaq Composite — gained 1.8% and 3.1%, respectively, whereas the Dow Jones Industrial Average ended virtually unchanged. This clearly shows indecisiveness in the market despite solid corporate earnings.From January through March 2024, the U.S. economy grew at the slowest pace in nearly two years at 1.6% against the Wall Street expectation of 2.4%. The numbers suggest a significant loss of momentum since the beginning of 2024 due to a sharp rise in inflation which led to a cool-off in consumer and government spending.Also, the personal consumption expenditure price index rose 3.4% in the first quarter against 1.8% in the previous quarter. This raised concerns over rising inflation and the timing of the planned rate cuts by the Federal Reserve.On the international front, rising geopolitical tension between Israel and its neighbors, are still a concern for global oil prices and supply chain, which could lead","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/llEIJtlHISQ_iDpj2RC5GA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/debc48c0a0afd8d3a2d2dcb320e026fe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/llEIJtlHISQ_iDpj2RC5GA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/debc48c0a0afd8d3a2d2dcb320e026fe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beat-market-zacks-way-adma-121600323.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2430468038","title":"3 'Buy-Rated' Biotech Stocks Under $10","url":"https://stock-news.laohu8.com/highlight/detail?id=2430468038","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2430468038?lang=en_us&edition=fundamental","pubTime":"2024-04-28 16:39","pubTimestamp":1714293542,"startTime":"0","endTime":"0","summary":"Today, we look at three small-cap biotech/biopharma stocks.All three have attractive risk/reward profiles and potential catalysts on the horizon.An investment synopsis on all three firms is presented ","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172783897/image_172783897.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/172783897/image_172783897.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4687081-3-buy-rated-biotech-stocks-under-10","is_publish_highlight":false,"gpt_icon":0},{"id":"2430726282","title":"Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2430726282","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2430726282?lang=en_us&edition=fundamental","pubTime":"2024-04-26 05:45","pubTimestamp":1714081518,"startTime":"0","endTime":"0","summary":"In the latest market close, Adma Biologics  reached $6.44, with a -0.31% movement compared to the previous day. The stock's performance was ahead of the S&P 500's daily loss of 0.46%. Elsewhere, the Dow lost 0.98%, while the tech-heavy Nasdaq lost 0.64%.Heading into today, shares of the infectious disease drug developer had lost 4.15% over the past month, outpacing the Medical sector's loss of 4.9% and lagging the S&P 500's loss of 3.04% in that time.The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is expected to report EPS of $0.05, up 266.67% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $76.7 million, indicating a 34.77% increase compared to the same quarter of the previous year.Investors should also note any recent changes to analyst estimates for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revis","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/F3nzpi36wi9juoO_v9PrEA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/F3nzpi36wi9juoO_v9PrEA--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/2a50596f066181e48e4ae0ad6be00462"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-stock-moves-214518603.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429506524","title":"Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2429506524","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429506524?lang=en_us&edition=fundamental","pubTime":"2024-04-24 20:50","pubTimestamp":1713963007,"startTime":"0","endTime":"0","summary":"When it comes to short-term investing or trading, they say \"the trend is your friend.\" And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, etc. -- that could keep the momentum in the stock going.Our \"Recent Price Strength\" screen, which is created on a unique short-term trading strategy, could be pretty useful in this regard. This predefined screen makes it really easy to shortlist the stocks that have enough fundamental strength to maintain their recent uptrend. Also, the screen passes only the stocks that are trading in the upper portion of their 52-week high-low range, which is usually an indicator of bullish","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/apbC75v0joJeGGZArvqIvw--~B/aD02NzU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/105b2acef7bf0873f24b78932b1fdc3c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/recent-price-trend-adma-biologics-125007901.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429895145","title":"Corcept (CORT) Posts Positive Data From Cushing's Syndrome Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2429895145","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429895145?lang=en_us&edition=fundamental","pubTime":"2024-04-24 00:12","pubTimestamp":1713888720,"startTime":"0","endTime":"0","summary":"Corcept Therapeutics Incorporated CORT announced positive data from one part of the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with all etiologies of endogenous Cushing’s syndrome.The GRACE study consists of two parts. The above mentioned data was from the open-label portion of the study in which patients with Cushing’s syndrome and either hypertension, hyperglycemia or both were treated with relacorilant for a period of 22 weeks.Data from the open-label phase of the study showed that treatment with relacorilant led to clinically meaningful and statistically significant improvements in hypertension, hyperglycemia as well as other key secondary and exploratory endpoints.Per the company, patients who experienced pre-specified improvements in either or both symptoms were allowed to enter the GRACE study’s randomized withdrawal phase, in which half of the patients were treated with relacorilant while the other half was gi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_LT6pKD_Fk90UGSt.TnE5Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_LT6pKD_Fk90UGSt.TnE5Q--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e10425bef32c421f16ccc0d2a8c8bb61"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/corcept-cort-posts-positive-data-161200336.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429143749","title":"Sanofi (SNY) Rilzabrutinib Shows Benefit in Blood Disorder Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2429143749","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429143749?lang=en_us&edition=fundamental","pubTime":"2024-04-24 00:03","pubTimestamp":1713888180,"startTime":"0","endTime":"0","summary":"Sanofi SNY announced positive data from the phase III LUNA 3 study, which evaluated its covalent BTK inhibitor, rilzabrutinib, for treating patients with immune thrombocytopenia , an autoimmune blood disorder.The LUNA 3 study evaluated the safety and efficacy of rilzabrutinib versus placebo in adult and adolescent patients with persistent or chronic ITP.Data from the study showed that treatment with twice-daily oral rilzabrutinib  led to durable platelet response, the primary endpoint of the LUNA 3 study, in significantly higher proportion of adult patients with persistent or chronic ITP as compared to placebo.The data underscore the potential of rilzabrutinib to provide a clinically meaningful benefit to patients living with ITP. Moreover, the safety profile of rilzabrutinib was similar to that seen in previous clinical studies.Building on the success of the LUNA 3 study, SNY plans to make regulatory filings for rilzabrutinib in ITP in the United States and in the European Union by 20","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sanofi-sny-rilzabrutinib-shows-benefit-160300493.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429118943","title":"Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2429118943","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429118943?lang=en_us&edition=fundamental","pubTime":"2024-04-23 20:09","pubTimestamp":1713874140,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals IncorporatedVRTX announced that it has entered into a licensing and collaboration agreement with France-based biotech company, TreeFrog Therapeutics, to optimize the production ofVRTX's type 1 diabetes  cell therapies.The agreement will grant the pharmaceutical company an exclusive license to TreeFrog's proprietary cell manufacturing technology, C-Stem, which will be leveraged by VRTX to enhance its ability to generate large amounts of fully differentiated insulin-producing pancreatic islet cellsfor its portfolio of T1D cell therapies.TreeFrog’s C-Stem technology imitates the natural microenvironment of cells that facilitates those cells to grow exponentially in a three-dimensional setting.Year to date, shares of Vertex have lost 1.7% compared with the industry’s 11.1% decline.Per the terms of the agreement, VRTX is liable to make an upfront payment of $25 million to TreeFrog in consideration of the C-Stem license grant while making an equity investment in the pa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/exICdiN3pRo85wyejmNeSw--~B/aD0zNDk7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f505d3082c5c32dd86790426e65a15d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/exICdiN3pRo85wyejmNeSw--~B/aD0zNDk7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9f505d3082c5c32dd86790426e65a15d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vertex-vrtx-treefrog-sign-deal-120900841.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429190641","title":"Will Alkermes' (ALKS) Proprietary Drugs Aid Amid Competition?","url":"https://stock-news.laohu8.com/highlight/detail?id=2429190641","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429190641?lang=en_us&edition=fundamental","pubTime":"2024-04-23 02:14","pubTimestamp":1713809640,"startTime":"0","endTime":"0","summary":"Alkermes plc ALKS has made steady progress with its portfolio of proprietary products — Vivitrol , Aristada  and Lybalvi  that are witnessing a steady uptake and driving growth.The continued growth in the alcohol-dependence treatment market has driven new patients toward Vivitrol, while Aristada sales have been driven by underlying demand in recent quarters.Lybalvi , which is approved for the treatment of adults with schizophrenia and adults who have bipolar I disorder, has witnessed strong sales uptake so far and has exceeded management’s expectations.Alkermes’ set of proprietary products has generated combined sales worth $920 million in 2023, reflecting an increase of 18.3% on a year-over-year basis.Shares of Alkermes have lost 14% year to date compared with the industry’s 11% decline.Earlier this month, Alkermes announced positive top-line data from a phase Ib study evaluating its novel, investigational, oral orexin 2 receptor  agonist, ALKS 2680, as a once-daily treatment for narc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alkermes-alks-proprietary-drugs-aid-181400273.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429594972","title":"Here's Why You Should Add Immunovant (IMVT) to Your Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2429594972","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2429594972?lang=en_us&edition=fundamental","pubTime":"2024-04-22 23:53","pubTimestamp":1713801180,"startTime":"0","endTime":"0","summary":"Immunovant, Inc.IMVT is a New York-based biopharmaceutical company, which develops monoclonal antibodies for the treatment of autoimmune diseases. The company currently has no marketed products in its commercial portfolio.Immunovant’s clinical-stage pipeline comprises its lead product candidate, batoclimab , and a new candidate, IMVT-1402, which are being developed as a subcutaneous injection for the treatment of IgG-mediated autoimmune diseases.Top-line data from the pivotal study evaluating batoclimab for the treatment of MG is expected in the second half of 2024. Initial data readouts from two additional phase III studies evaluating batoclimab for treating TED are expected in the first half of 2025.Batoclimab is also being studied to treat other indications, which include chronic inflammatory demyelinating polyneuropathy  and Graves’ disease . Top-line results from the pivotal phase IIb study evaluating batoclimab to treat CIDP are expected in the second or third quarter of 2024.Thu","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-add-immunovant-imvt-155300709.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428618187","title":"Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2428618187","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428618187?lang=en_us&edition=fundamental","pubTime":"2024-04-20 05:45","pubTimestamp":1713563121,"startTime":"0","endTime":"0","summary":"Adma Biologics  ended the recent trading session at $6.27, demonstrating a +1.13% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.88%. On the other hand, the Dow registered a gain of 0.56%, and the technology-centric Nasdaq decreased by 2.05%.The the stock of infectious disease drug developer has risen by 0.16% in the past month, leading the Medical sector's loss of 6.4% and the S&P 500's loss of 2.57%.The upcoming earnings release of Adma Biologics will be of great interest to investors. The company is forecasted to report an EPS of $0.05, showcasing a 266.67% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $76.7 million, indicating a 34.77% upward movement from the same quarter last year.Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Adma Biologics. Recent revisions tend t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/e0VWXB5.wUFiKGuJPPpLzg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a7cdcede0bb5a646be035f4a7e678781"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-ascends-while-214521137.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428670976","title":"Vertex (VRTX) Begins Rolling NDA Filing for Acute Pain Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2428670976","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428670976?lang=en_us&edition=fundamental","pubTime":"2024-04-19 23:57","pubTimestamp":1713542220,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals IncorporatedVRTX announced that the FDA has granted a rolling new drug application  submission for suzetrigine  in moderate-to-severe acute pain.The company has already initiated the rolling submission process and is on track to complete the NDA submission in the second quarter of 2024.Suzetrigine is an investigational orally administered selective NaV1.8 pain signal inhibitor. The rolling NDA submission is supported by encouraging results from the company’s phase III program for suzetrigine in acute pain management.In January 2024, Vertex reportedthat it had met the primary endpoints in three phase III studies evaluating suzetrigine to treat moderate-to-severe acute pain. The late-stage studies included two pivotal phase III acute pain studies, one following bunionectomy surgery and the other following abdominoplasty surgery, and a 14-day single-arm phase III study across a broad range of other surgical and non-surgical acute pain conditions.Furthermore, both la","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UgiI07ytew_hNcL7MgLFiA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UgiI07ytew_hNcL7MgLFiA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vertex-vrtx-begins-rolling-nda-155700578.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428771669","title":"Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2428771669","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428771669?lang=en_us&edition=fundamental","pubTime":"2024-04-19 22:14","pubTimestamp":1713536040,"startTime":"0","endTime":"0","summary":"The novel AML therapy, BP1002, is being developed by leveraging Bio-Path’s proprietary DNAbilize antisense RNAi nanoparticle technology. Per the company, BP1002 targets the Bcl-2 protein, which is responsible for driving cell survival in up to 60% of all cancers.Venetoclax, an oral Bcl-2 inhibitor, in combination with a hypomethylating agent or with low-dose cytarabine, is currently the standard-of-care  therapy for patients with AML who are not eligible for intensive chemotherapy.Per the announcement, Bio-Path has completed the testing of both the 20 and 40 mg/m2 dose levels of BP1002 and the study will pause for a brief data review by the FDA. Contingent upon successful feedback, the company expects to initiate testing the next planned higher dose of BP1002  as a monotherapy in the dose-escalation portion of the phase I/Ib AML study.The stock soared 30% in the last trading session on Apr 18 driven by the encouraging developmental update for BP1002 from the AML program. Year to date, ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/b7YQi_HTDu1GkQZqPUqgyw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59b208c03ab625710a229f805a232093"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bio-path-bpth-rises-upbeat-141400907.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428510238","title":"Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal","url":"https://stock-news.laohu8.com/highlight/detail?id=2428510238","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428510238?lang=en_us&edition=fundamental","pubTime":"2024-04-18 23:37","pubTimestamp":1713454620,"startTime":"0","endTime":"0","summary":"Shares of Sage Pharmaceuticals SAGE dropped 19.6% on Wednesday after management shared topline results from the phase II PRECEDENT study  evaluating its lead neuropsychiatric candidate dalzanemdor in patients with mild cognitive impairment  associated with Parkinson’s disease .The study failed to achieve its primary endpoint of demonstrating a statistically significant difference from baseline in participants treated with orally-administered dalzanemdor, when compared to placebo. Per management, the analyses of data also did not indicate any meaningful differences versus placebo in the other exploratory endpoints, such as SCOPA-Cog.Management also pointed out that 48 patients, which represent more than half of the total study participants, experienced treatment emergent adverse events  ranging from mild to moderate in severity.Year to date, shares of Sage have lost 42.0% compared with the industry’s 11.2% fall.Following the above setbacks and to support Zurzuvae’s commercial launch, Sa","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-sage-down-20-parkinsons-153700289.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428899519","title":"DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch","url":"https://stock-news.laohu8.com/highlight/detail?id=2428899519","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428899519?lang=en_us&edition=fundamental","pubTime":"2024-04-18 22:06","pubTimestamp":1713449160,"startTime":"0","endTime":"0","summary":"DiaMedica Therapeutics Inc.DMAC announced that it has dosed the first patient in the relaunch of its mid to late-stage stage pivotal study evaluating the safety and efficacy of its lead product candidate, DM199, to treat acute ischemic stroke . The company’s shares gained 9.7% on Apr 17, following the encouraging news.DM199 is DiaMedica’s recombinant  form of human tissue kallikrein-1, which will be developed in the pivotal phase II/III ReMEDy2 study for AIS patients. The investigational candidate’s novel mechanism of action aims at enhancing collateral blood flow in the brain tissues affected by the stroke.In 2022, the FDA placed a clinical hold on DiaMedica’s ReMEDy2 study of DM199 based on three reports of serious treatment-related adverse events. It was observed that those three AIS patients experienced clinically significant transient hypotension , shortly after initiation of the intravenous  dose of DM199.Additionally, the blood pressure levels of the three patients recovered bac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.UMP6LIbiG0Pb3tKR9RYYw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/diamedica-dmac-stroke-study-dosing-140600275.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428190735","title":"Vanda (VNDA) Rejects Takeover Interest From Future Pak, Stock Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2428190735","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428190735?lang=en_us&edition=fundamental","pubTime":"2024-04-18 21:44","pubTimestamp":1713447840,"startTime":"0","endTime":"0","summary":"Vanda Pharmaceuticals Inc. VNDA announced that its board of directors has unanimously rejected a potential acquisition bid by Future Pak, LLC wherein the latter proposed to acquire all the outstanding shares of VNDA.Shares of Vanda were up 29.4% on Apr 17 following the announcement of the news.VNDA has been receiving several voluntary takeover proposals from Future Pak, the latest being offered on Apr 1 for $7.25-$7.75 per share, subject to certain terms and conditions.Following thorough discussions with its independent financial and legal advisors, Vanda’s board of directors carefully reviewed the proposed takeover interest and concluded that it significantly undervalues the company and is not in its best interests and that of the shareholders.Per management, the proposed takeover interest is likely to create significant value for Future Pak at the expense of Vanda’s shareholders and would not likely create reasonable value for the company and its stockholders.Vanda shareholders will ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.WQmSb1MJO1_eLnmBVS1zA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vanda-vnda-rejects-takeover-interest-134400616.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428303045","title":"Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note","url":"https://stock-news.laohu8.com/highlight/detail?id=2428303045","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428303045?lang=en_us&edition=fundamental","pubTime":"2024-04-18 05:50","pubTimestamp":1713390619,"startTime":"0","endTime":"0","summary":"In the latest trading session, Adma Biologics  closed at $6.04, marking a -1.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 0.58%. On the other hand, the Dow registered a loss of 0.12%, and the technology-centric Nasdaq decreased by 1.15%.Prior to today's trading, shares of the infectious disease drug developer had lost 0.48% over the past month. This has was narrower than the Medical sector's loss of 6.07% and the S&P 500's loss of 1.09% in that time.The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release. It is anticipated that the company will report an EPS of $0.05, marking a 266.67% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $76.7 million, showing a 34.77% escalation compared to the year-ago quarter.To read this article on Zacks.com click here.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/nxwFIPS2ImeTQYZMYlnAgg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1a018a29aef5adbf5b4319f32058e209"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adma-biologics-adma-registers-bigger-215019733.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2428220328","title":"Are Medical Stocks Lagging  Annexon (ANNX) This Year?","url":"https://stock-news.laohu8.com/highlight/detail?id=2428220328","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2428220328?lang=en_us&edition=fundamental","pubTime":"2024-04-17 21:40","pubTimestamp":1713361210,"startTime":"0","endTime":"0","summary":"For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Annexon, Inc.  one of those stocks right now?A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Annexon, Inc. is a member of the Medical sector. This group includes 1051 individual stocks and currently holds a Zacks Sector Rank of #2. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. Annexon, Inc. is currently sporting a Zacks Rank of #2 .","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/XxozWWpdDFgGg6m0CzltLg--~B/aD02MDI7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/45c083e4721b0d0d1f6e431ec0bb5cc1"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medical-stocks-lagging-annexon-annx-134010392.html","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.admabiologics.com","stockEarnings":[{"period":"1week","weight":0.0466},{"period":"1month","weight":0.0466},{"period":"3month","weight":0.2887},{"period":"6month","weight":0.8466},{"period":"1year","weight":0.9368},{"period":"ytd","weight":0.4912}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.036203},{"month":2,"riseRate":0.5,"avgChangeRate":-0.013938},{"month":3,"riseRate":0.6,"avgChangeRate":0.097898},{"month":4,"riseRate":0.6,"avgChangeRate":0.007327},{"month":5,"riseRate":0.7,"avgChangeRate":0.032905},{"month":6,"riseRate":0.111111,"avgChangeRate":-0.078722},{"month":7,"riseRate":0.666667,"avgChangeRate":0.114663},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.032938},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.039779},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.036554},{"month":11,"riseRate":0.555556,"avgChangeRate":0.062096},{"month":12,"riseRate":0.4,"avgChangeRate":-0.05303}],"exchange":"NASDAQ","name":"ADMA Biologics","nameEN":"ADMA Biologics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ADMA Biologics,ADMA,ADMA Biologics股票,ADMA Biologics股票老虎,ADMA Biologics股票老虎国际,ADMA Biologics行情,ADMA Biologics股票行情,ADMA Biologics股价,ADMA Biologics股市,ADMA Biologics股票价格,ADMA Biologics股票交易,ADMA Biologics股票购买,ADMA Biologics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ADMA Biologics(ADMA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ADMA Biologics(ADMA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction